Developing Guidance on Naming, Labeling, and Packaging Practices to Reduce Medication Errors; Public Workshop; Request for Comments
Notice Of Public Workshop; Request For Comments.
The Food and Drug Administration (FDA) is announcing a public workshop entitled “Developing Guidance on Naming, Labeling, and Packaging Practices to Reduce Medication Errors.” The purpose of the public workshop is to initiate constructive dialogue and information sharing among regulators, researchers, the pharmaceutical industry, health care organizations, health care professionals, and others from the general public about the design of drug and therapeutic biologic container labels, carton labeling, and product packaging, and practices to develop proprietary names to reduce medication errors. The input from this workshop will be used to develop draft guidance for industry on practices for naming, labeling, and packaging of drugs and biologics to reduce the potential for medication errors. FDA is also opening a public docket to receive comments on this topic to assist in the development of draft guidance.
Table of Contents Back to Top
DATES AND TIME: Back to Top
The public workshop will be held on Thursday and Friday, June 24 and 25, 2010, from 8:30 a.m. to 5 p.m. each day. Register to make a presentation at the workshop by May 25, 2010. See section IV of this document for information on how to attend or present at the meeting. Submit written or electronic comments to the docket by July 23, 2010, to receive consideration.
ADDRESSES: Back to Top
The public workshop will be held at the Marriott Residence Inn at 7335 Wisconsin Ave., Bethesda, MD 20814. Submit electronic requests to register and make a presentation to GNLP.email@example.com. Submit written requests to register and make a presentation to Colleen O'Malley (see FOR FURTHER INFORMATION CONTACT).
Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Back to Top
Colleen O'Malley, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 4305, Silver Spring, MD 20993, 301-796-1786, FAX: 301-796-9832, email: firstname.lastname@example.org.
SUPPLEMENTARY INFORMATION: Back to Top
I. Background Back to Top
In title I of the Food and Drug Administration Amendments Act of 2007 (FDAAA) (Public Law 110-85), Congress reauthorized and expanded the Prescription Drug User Fee Act program for fiscal years (FYs) 2008 through 2012 (PDUFA IV). As part of the performance goals and procedures set forth in an enclosure to the letter from the Secretary of the Health and Human Services referred to in section 101(c) of FDAAA, FDA committed to certain performance goals and procedures. (See http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm119243.htm). In that letter, FDA stated that it would use fees collected under PDUFA to implement various measures to reduce medication errors related to look-alike and sound-alike proprietary names, unclear label abbreviations, acronyms, dose designations, and error-prone label and packaging designs. Among these measures, FDA agreed that by the end of FY 2010, after public consultation with academia, industry, and others from the general public, the agency would publish a draft guidance describing practices for naming, labeling, and packaging drugs and biologics to reduce medication errors.
II. Workshop Objectives and Issues for Discussion Back to Top
This workshop represents the first step in meeting the PDUFA goal described previously and is intended to provide valuable information to assist the agency in developing draft guidance for industry on practices to reduce medication errors. The workshop will not discuss the ongoing FDA pilot program to evaluate proposed proprietary name submissions. Persons seeking more information on the pilot program should refer to the FDA concept paper entitled “PDUFA Pilot Project Proprietary Name Review” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm072229.pdf and the Federal Register notice entitled “Pilot Program to Evaluate Proposed Proprietary Name Submissions; Procedures to Register for Participation and Submit Data” (74 FR 50806, October 1, 2009) announcing procedures for participation in the voluntary pilot program.
The workshop objectives are as follows: (1) Initiate constructive dialogue and information sharing among regulators, researchers, the pharmaceutical industry, health care organizations, health care professionals, and others from the general public about the design of drug and therapeutic biologic container labels, carton labeling, and product packaging, and practices in developing proprietary names to reduce medication errors; (2) share current FDA experience regarding the evaluation of labels, packaging, and proprietary names; and (3) obtain input on developing consistent review criteria for FDA to use in evaluating container labels, carton labeling, and product packaging submitted to the agency. FDA will use information from the workshop to help develop a draft guidance for manufacturers and distributors for creating product names and designing product labels and packaging to reduce medication errors.
Four panel discussions will focus on areas in which the agency requests input.
Panel 1 will focus on characteristics of container label and carton labeling design as they relate to reducing the risk of medication errors. Topics with respect to container label and carton labeling design include content, format, type of label, layout, use of color, use of graphics, and costs associated with designing labels.
Panel 1 will address the following questions:
1. What does FDA need to consider to ensure that the container labels and carton labeling designs are safe and reduce the risk of medication errors?
2. What are the challenges in designing container label and carton labeling to reduce the risk of medication errors?
3. What are some strategies for addressing these design challenges without compromising safety?
Panel 2 will focus on characteristics related to study design, conduct and interpretation of human factors analysis, Failure Mode and Effects Analysis (FMEA), usability studies, and other studies specifically focused on evaluating the safety of container label and carton labeling designs to reduce the risk of medication errors. Topics include methodology, selection of participants and subjects, collection of data, analysis of data, costs and time to conduct such studies, and interpretation of study findings.
Panel 2 will address the following questions:
1. What are the strengths and limitations of performing such studies?
2. Are there other types of studies and analyses that provide useful information about the medication error risks associated with the container label or carton labeling design?
3. How can FDA ensure that the study design accurately captures and assesses potential medication error risks that should be considered in our evaluation of the container labels and carton labeling?
Panel 3 will focus on characteristics of the manufacturers' packaging used for medications as they relate to the safe use of the medicine from a medication errors perspective. Topics include medication error considerations when designing a container-closure system for a medication, drug-device combination packaging, studies and analyses to evaluate the safety of product packaging design, and costs associated with designing product packaging.
Panel 3 will address the following questions:
1. What information does FDA need to consider to ensure that the manufacturers' packaging design is safe and reduces the risk for medication errors?
2. What are the challenges in designing manufacturers' packaging to reduce the risk of medication errors?
3. What are some strategies for addressing these challenges without compromising safety?
4. How can FDA ensure that the study design accurately captures and assesses potential medication error risks that should be considered in our evaluation of a proposed manufacturers' packaging design for a particular medication?
5. Are there other types of studies and analyses that provide useful information about the medication error risks associated with the manufacturers' packaging design?
Panel 4 will focus on recommended practices in developing proprietary names as they relate to reducing medication errors. Topics include choosing a nomenclature strategy for new products containing the same active ingredient as marketed products; selection and application of modifiers to proprietary names; and medication error potential from use of the same proprietary name as a component of the proprietary names for multiple products containing different active ingredients; U.S. Adopted Names (USAN) Council Stems; medical abbreviations; encoding dosage forms or dosing intervals; and including the established name or ingredients within the proprietary name.
Panel 4 will address the following questions:
1. What are the challenges in developing a proprietary name from a safety perspective to prevent medication errors?
2. What are some strategies for addressing these challenges without compromising safety?
3. When products are developed containing the same ingredient as a marketed product, how can risks associated with a given nomenclature strategy for the proposed product be evaluated, minimized, and mitigated (e.g., use of a modifier “Proprietary XL” versus the use of an alternate proprietary name)?
III. Comments Back to Top
Regardless of attendance at the public workshop, interested persons may submit written or electronic comments to the Division of Dockets Management (see ADDRESSES). Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
IV. Attendance and Registration Back to Top
There is no fee to attend the workshop, and attendees who do not wish to make a formal presentation do not need to register. Seating will be on a first-come, first-served basis.
If you would like to make an oral presentation to the panelists during the meeting, you must register by mail or email (see ADDRESSES) and provide an abstract of your presentation by 5 p.m. on May 25, 2010. You must also provide your name, title, business affiliation (if applicable), address, telephone and fax numbers, and e-mail address. Identify the panel number and question number(s) you will address in your presentation.
FDA will do its best to accommodate requests to speak. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations and request time for a joint presentation. FDA will determine the amount of time allotted to each presenter and the approximate time that each oral presentation is scheduled to begin. Persons registered to make a formal presentation should check in before the workshop. Ample time will be allowed during the scheduled agenda for attendees who have not registered to ask questions of the panelists. In addition, we strongly encourage written comments to the docket.
If you need special accommodations because of disability, please contact Colleen O'Malley (see FOR FURTHER INFORMATION CONTACT) at least 7 days before the workshop.
V. Transcripts Back to Top
Please be advised that as soon as a transcript of the workshop is available, it will accessible at http://www.regulations.gov. It may be viewed at the Division of Dockets Management (see ADDRESSES). A transcript will also be made available in either hard copy or on a CD-ROM upon submission of a Freedom of Information request. Written requests are to be sent to Freedom of Information (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 6-30, Rockville, MD 20857.
Dated: March 31, 2010.
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-8233 Filed 4-9-10; 8:45 am]
BILLING CODE 4160-01-S